Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion January 2, 2019 • 7:00 AM EST
Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement December 18, 2018 • 7:00 AM EST
Tonix Pharmaceuticals Announces Closing of $15,000,000 Public Offering December 11, 2018 • 4:00 PM EST
Tonix Pharmaceuticals Announces Additional Details of the New Phase 3 Study of Tonmya® for PTSD, Following Receipt of FDA Minutes November 29, 2018 • 7:00 AM EST
Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights November 9, 2018 • 7:30 AM EST
Tonix Pharmaceuticals Announces New Patent Coverage Protecting Tonmya® November 7, 2018 • 7:00 AM EST
Tonix Pharmaceuticals Presented Results and Retrospective Analyses of Phase 3 P301 “HONOR” Study in Poster Presentation at CNS Summit 2018 November 6, 2018 • 7:00 AM EST
